Currently, there are two assays approved by the FDA for testing EGFR mutations in lung cancers, the cobas EGFR mutation test (Roche Molecular Systems, Branchburg, NJ) and the therascreen EGFR RGQ PCR Kit (Qiagen, Hilden, Germany) [9–13]. Here, EGFR is linked to lung carcinoma.